INS and Alzheimer disease: There is an increasing effort to develop novel AD therapeutics based on the promotion of IR-signaling processes by either directly inducing IR activation (e.g., nasal insulin inhalation [55–57]) or by applying insulin-sensitization measures (e.g., PPARγ activators [41, 58, 59]) that stimulate downstream IR-signaling.